NCT06652100 - Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults | Biotech Hunter

Enrollment

800

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

January 31, 2026

Conditions

Acute Kidney Injury

Interventions

DIAGNOSTIC_TEST

ProNephro AKI (NGAL)

ProNephro AKI™ (NGAL) is an immunoassay for the in vitro quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine.

Trial Locations (12)

10032

RECRUITING

Columbia University, New York

21224

NOT_YET_RECRUITING

Johns Hopkins University, Baltimore

27109

RECRUITING

Wake Forest University, Winston-Salem

29425

NOT_YET_RECRUITING

Medical University of South Carolina, Charleston

35233

RECRUITING

The University of Alabama, Birmingham

44195

RECRUITING

Cleveland Clinic, Cleveland

48109

RECRUITING

University of Michigan, Ann Arbor

60637

RECRUITING

University of Chicago, Chicago

87131

RECRUITING

University of New Mexico, Albuquerque

95817

RECRUITING

UC Davis, Sacramento

06510

RECRUITING

Yale University, New Haven

02114

RECRUITING

Massachusetts General Hospital, Boston